Clinical trial · Interventional
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
A Phase I, Open-label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
NCT04144855CI-TRIAL-00041366unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in patients with advanced malignant tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TQB3474 injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TQB3474 injection
- description
- Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.
- interventionNames
- Drug: TQB3474 injection
Primary outcomes (1)
- measure
- Dose-limiting toxicity (DLT)
- timeFrame
- Baseline up to 28 days
- description
- Subjects appear the following toxic reaction relate to the drug after treatment within 28 days ：III °or above of non-hematological toxicity, IV° hematological toxicity , III ° neutropenia associated with fever, III ° thrombocytopenia with bleeding.
Secondary outcomes (3)
- measure
- Cmax
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1.18 and 70 years old. 2\. Histologically or cytologically confirmed advanced solid tumors. 3\. Has the surgery more than 4 weeks before the first dose. 4\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1. 5\. Life expectancy ≥12 weeks. 6\. Adequate organ system function. 7\. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study. 8\. Understood and signed an informed consent form. Exclusion Criteria: 1. Has received chemotherapy or radiotherapy within 4 weeks before the first dose. 2. Hypersensitivity to TQB3474 or its excipient. 3. Has factors that impact on intravenous infusion of drugs and venous blood collection. 4. Has severe gastrointestinal disease within 4 weeks before the first dose. 5. Has severe eye disease. 6. Breastfeeding or pregnant women. 7. Has brain metastases. 8. HCV antibody and HCV-RNA positive; Syphilis positive; HBsAg positive and HBV DNA positive (≥1000 copies /mL). 9. Has infection that need systemic treatment during screening. 10. Has participated in any other clinical trial within 4 weeks before the first dose. 11. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
References
Publications (0)
Data not yet available
No reference posted for this study.